Aggregation of biopharmaceuticals in human plasma and human serum: implications for drug research and development - Wikidata - awgldk - TriplyDB

Aggregation of biopharmaceuticals in human plasma and human serum: implications for drug research and development

Aggregation of biopharmaceuticals in human plasma and human serum: implications for drug research and development

http://www.wikidata.org/entity/Q34212786

about

Posttranslational Modifications and the Immunogenicity of Biotherapeutics Selective assembly of DNA-conjugated single-walled carbon nanotubes from the vascular secretome.Dextrose-mediated aggregation of therapeutic monoclonal antibodies in human plasma: Implication of isoelectric precipitation of complement proteins Quality control and stability studies with the monoclonal antibody, trastuzumab: application of 1D- vs. 2D-gel electrophoresis.Diffusion of Soluble Aggregates of THIOMABs and Bispecific Antibodies in Serum.Cancer Chemotherapy Update: Bevacizumab, Etoposide, and Cisplatin Regimen for Refractory Brain Metastases.Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization.

P2860

Q26748614-E5646572-BB0F-4D70-8C3A-7E17D810CF2B Q34239172-F3BDC3DA-2AC7-422D-ABEB-18288CF59756 Q37138219-9E827A8B-AB69-49A6-92C1-65DB33501142 Q39357941-50BF0294-6559-462E-A639-F35E3D166332 Q47144575-0860EF0C-1397-459E-A7CA-2174992CD2D1 Q47185642-7F19A870-543C-45AA-B88C-629B4C1CFA70 Q51486721-391ECA80-C473-4ACC-8917-236ADAA8148B

P2860

Aggregation of biopharmaceuticals in human plasma and human serum: implications for drug research and development

http://www.wikidata.org/entity/Q34212786

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Aggregation of biopharmaceutic ...... drug research and development

@ast

Aggregation of biopharmaceutic ...... drug research and development

@en

Aggregation of biopharmaceutic ...... drug research and development

@nl

type

label

Aggregation of biopharmaceutic ...... drug research and development

@ast

Aggregation of biopharmaceutic ...... drug research and development

@en

Aggregation of biopharmaceutic ...... drug research and development

@nl

prefLabel

Aggregation of biopharmaceutic ...... drug research and development

@ast

Aggregation of biopharmaceutic ...... drug research and development

@en

Aggregation of biopharmaceutic ...... drug research and development

@nl

P1433

Q34212786-4AE559A7-2986-4B2A-97DD-015DBEBAEA66

P1476

Q34212786-C812184E-FD08-483A-A526-E057B865470D

P2093

Q34212786-089A4F96-55E8-4200-9399-98F444B8893C

Q34212786-8FAD145C-CC2C-49D4-B5A3-02A7986399C0

Q34212786-95E9B10C-E369-438D-8B55-0DFBD813B28F

Q34212786-ABEA06E1-FA94-4991-9F85-66FAE4A3BDEE

Q34212786-B7B3D0DC-9DBA-4D21-9D94-3FEF38F72584

Q34212786-CA4CBBE5-203A-442E-9BE5-E66E9142D193

Q34212786-F92B4C40-D00C-4B95-A39D-C490728A4B32

P2860

Q34212786-058C209A-597E-4E37-84FE-F80A5BA949F6

Q34212786-06C023B4-7BEB-4A96-8097-7A5B148F2111

Q34212786-25A83EC6-23A8-4387-87CD-B1A17B5B136A

Q34212786-29C690A1-9CC3-4C63-92D8-685C43FCF9D4

Q34212786-33E02344-3417-44B8-9A18-91EDF3F0E750

Q34212786-4F138D35-694A-46C1-823D-6D16FC06AA5F

Q34212786-52254E17-D81C-4A57-BE93-4DB548E47BC5

Q34212786-596C26E9-FFBD-4B72-8E57-19D49DEF9413

Q34212786-6C72049B-A525-4C50-A15A-38A4023D2E86

Q34212786-71559D0E-430B-4DB3-B28C-B3844CCFE87B

P304

Q34212786-D0A5089D-220D-4588-9E2F-1C8DAD92325E

P31

Q34212786-BE0DFED1-0875-46D1-9F81-2C75CC447F6C

P356

Q34212786-346A5334-0C4E-47FC-9276-ED2AE3E0FA79

P433

Q34212786-BBE6C106-A415-4668-AE61-F8B02EF36C02

P478

Q34212786-92AAF475-34AD-4B68-B018-81A088826130

P577

Q34212786-82032AB8-C849-434B-A913-13EBACBDF998

P5875

Q34212786-C739B30B-4D33-47CE-ACE8-3AEFA485D022

P698

Q34212786-6AD3CC2A-5A30-46A5-B460-1437BEA8B4FF

P932

Q34212786-41B70D52-F584-46BC-A2F1-A9AC425BDA9B

P356

P1433

Monoclonal Antibodies

P1476

Aggregation of biopharmaceutic ...... drug research and development

@en

P2093

Caroline Palais

http://www.w3.org/2001/XMLSchema#string

Chakravarthy Narasimhan

http://www.w3.org/2001/XMLSchema#string

Erin Green-Trexler

http://www.w3.org/2001/XMLSchema#string

Henryk Mach

http://www.w3.org/2001/XMLSchema#string

Mohammed Shameem

http://www.w3.org/2001/XMLSchema#string

Sonia Gregory

http://www.w3.org/2001/XMLSchema#string

Tudor Arvinte

http://www.w3.org/2001/XMLSchema#string

P2860

High throughput screening of protein formulation stability: practical considerations.

Measurement of fluid viscosity at microliter volumes using quartz impedance analysis.

Detection and characterization of subvisible aggregates of monoclonal IgG in serum

Bioequivalence and the immunogenicity of biopharmaceuticals.

Immunogenicity of therapeutic proteins: clinical implications and future prospects.

Epoetin-induced pure red cell aplasia: diagnosis and treatment.

Nature and consequences of protein-protein interactions in high protein concentration solutions.

Protein aggregation: pathways, induction factors and analysis.

An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics.

A therapeutic antibody and its antigen form different complexes in serum than in phosphate-buffered saline: a study by analytical ultracentrifugation.

P304

491-500

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.24245

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236187602

http://www.w3.org/2001/XMLSchema#string

P698

23571158

http://www.w3.org/2001/XMLSchema#string

P932

4169040

http://www.w3.org/2001/XMLSchema#string